Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults
Status:
Completed
Trial end date:
2020-03-04
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the effect of a single therapeutic (50 mg)
oral dose of omecamtiv mecarbil (OM) on the QT interval / QT interval corrected for heart
rate (QTc), relative to placebo, in healthy adults.
The QT interval is the section on an electrocardiogram (ECG) that represents the time it
takes for the electrical system to fire an impulse through the ventricles and then recharge,
or the time it takes for the heart muscle to contract and then recover.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen Cytokinetics
Treatments:
Moxifloxacin Norgestimate, ethinyl estradiol drug combination